NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Thales Group

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Thales and Bertin Partner in CBRN Defence with Successful Tests of Biological Sampling and Identification for the PIABC PELICAN - Thales and Bertin Consolidate their Partnership in CBRN Defence with Successful Tests of Biological Sampling and Identification for the PIABC PELICAN Project - ThalesGroup.com
Thales and Bertin Partner in CBRN Defence with Successful Tests of Biological Sampling and Identification for the PIABC PELICAN

 

NewswireTODAY - /newswire/ - Paris, Ile-de-France, France, 2023/10/26 - Thales and Bertin Consolidate their Partnership in CBRN Defence with Successful Tests of Biological Sampling and Identification for the PIABC PELICAN Project - ThalesGroup.com. Euronext: HO

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Government trials were conducted over two weeks to assess the biological sampling and identification capabilities of the PIABC* PELICAN** platform as part of an advanced study project financed and managed by France's Defence Innovation Agency and the NBC management unit (UM NBC) at the French defence procurement agency (DGA).

Led by the French defence procurement agency's CBRN testing establishment (DGA Maîtrise NRBC), the trials were conducted by the 2nd Dragoon Regiment of the French Army stationed at Fontevraud and the CBRN intervention unit (UI NRBC) of the French Air and Space Force stationed at Cazaux, in the presence of representatives of the French Army’s Technical Section (STAT), senior staff from the nuclear security and CBRN unit at Cazaux, and industry partners.

The trials included:
• sampling with the COLIBRI system developed by Bertin
• sample unpacking and processing in the BAG isolator developed by EuroBioConcept
• sample preparation in the SAULEIL system developed by Thales
• transfer via the SPOT system developed by Bertin
• identification with the GENEXPERT system provided by Bertin.

All additional test equipment (dispersion, metrology, transfer, etc.) were provided by DGA Maîtrise NRBC and the armed forces.

The tests marked a significant milestone in the project, after four years of development, integration and industrial validation in close partnership with the Defence Innovation Agency and the procurement agency's UM NBC and Maîtrise NRBC units, and built on extensive feedback from the armed forced during equipment presentations and technical meetings.

The operation effectively validated the developments completed so far on the PIABC project and the level of maturity of the technologies involved. It underscored the value of the partnership between Thales and Bertin in the CBRN field, and confirmed Thales's role as a systems architect for civil and military CBRN defence systems.

Participants reiterated their interest in the latest system innovations, which were conclusively tested over the two-week campaign. The biological sampling and identification trials provided a golden opportunity for all the specialists involved to share their vision of the CBRN solutions of the future and gather feedback from all the parties involved.

* PIABC: Plateforme d’Intégration de technologies innovantes du domaine de l’Analyse Biologique et Chimique / Platform for the integration of innovative technologies in the domain of biological and chemical analysis
** PELICAN: Plate-forme d’Evaluation Logicielle pour l’Ingénierie et la Conception d’Architectures NRBC / Software platform for evaluation of engineering and architecture design of CBRN defence systems

About Thales

Thales (thalesgroup.com) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Thales Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Thales and Bertin Partner in CBRN Defence with Successful Tests of Biological Sampling and Identification for the PIABC PELICAN

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
PIABC PELICAN project | Thales Group
Contact: Press Office - ThalesGroup.com 
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Thales Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Thales Group / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Onivyde® Regimen, A Potential New Standard-of-care First-line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA
Frost & Sullivan and Trautec have Conducted An Extensive Investigation Across the Recombinant Type XVII Collagen Industry Chain
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Bushu Pharma Recognized with Frost & Sullivan’s 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing
STEMCELL Technologies Wins a Canada’s Most Admired Corporate Cultures™ of 2023 Award
BASF Pharma Solutions and IFF Pharma Solutions Establish Collaboration on Virtual Pharma Assistant Platform ZoomLab™
BASF Invests in Start-up 3Helix, Inc. to Jointly Bring Collagen-hybridizing Peptide Solutions to the Personal Care Market
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors
Ipsen Updates on E.U. Marketing Authorisation Application for Odevixibat in Alagille Syndrome
BASF Pharma Solutions Introduces 'VPA Premium Services' to its Virtual Pharma Assistants (VPAs) Digital Services Platform
NEC Selected by AMED for Design of A Universal Vaccine that is Effective Against Influenza Virus Strains
BostonGene, NEC and JIP Form Joint Venture in Japan
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib
US FDA Approves Ipsen’s Sohonos™ (palovarotene) Capsules, the First and Only Treatment for People with Fibrodysplasia Ossificans Progressiva
SCHOTT Pharma Strengthens Leading Position in the First Year as Stand-alone Company

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow, Inc.





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)